BPTH Stock Summary and Trading Ideas (Bio-Path Hldgs | NASDAQ:BPTH)

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Bio-Path Hldgs trades on the NASDAQ stock market under the symbol BPTH.

As of April 24, 2024, BPTH stock price declined to $2.49 with 156,766 million shares trading.

BPTH has a beta of 0.41, meaning it tends to be less sensitive to market movements. BPTH has a correlation of 0.00 to the broad based SPY ETF.

BPTH has a market cap of $3.90 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BPTH stock traded as high as $172.40 and as low as $2.46.

The top ETF exchange traded funds that BPTH belongs to (by Net Assets): VXF.

BPTH has underperformed the market in the last year with a price return of -91.1% while the SPY ETF gained +24.2%. BPTH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -69.7% and -34.8%, respectively, while the SPY returned +4.6% and -2.7%, respectively.

BPTH support price is $2.39 and resistance is $2.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BPTH stock will trade within this expected range on the day.